| Previous close | 49.70 |
| Open | 49.70 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 220.00 |
| Expiry date | 2023-03-17 |
| Day's range | 49.70 - 49.70 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Motley Fool
3 No-Brainer Growth Stocks to Buy in 2023
In last-year's difficult market, growth stocks were among the first to suffer. Why should we be confident about growth stocks? Moderna (NASDAQ: MRNA) went from zero product revenue prior to the pandemic to about $18 billion annually over the past two years.
- Business Wire
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
FREMONT, Calif., February 03, 2023--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform® as part of upcoming clinical studies evaluating mRNA-4157/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck, kn
- Motley Fool
Is Moderna Stock a Buy Now?
The past three years have been fascinating for Moderna (NASDAQ: MRNA) and its shareholders. Moderna's shares are up by an impressive 731% since early 2020, although its coronavirus-related sales will start falling this year. At this point, it's fair to ask if Moderna can march on and continue delivering market-beating returns, or if the company won't be worth an investment in a post-pandemic world.
